(British Society of Gastroenterology)
- Is the biogeography of the mucosa-associated microbiota a key factor affecting primary sclerosing cholangitis disease course and treatment?
- Statins for MAFLD/MASH: another brick in the wall while waiting for final answers
- Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
- Treatment of type 2 diabetes with MASLD: new evidence for personalised medicine
- Identifying colorectal cancer-specific vulnerabilities in the Wnt-driven long non-coding transcriptome
- Divergent lineage trajectories and genetic landscapes in human gastric intestinal metaplasia organoids associated with early neoplastic progression
- GI highlights from the literature
- Surveillance in inflammatory bowel disease: white light endoscopy with segmental re-inspection versus dye-based chromoendoscopy - a multi-arm randomised controlled trial (HELIOS)
- Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy
- Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohns disease: post hoc analysis of the RISK study
- Exploring the role of genetics, gut microbiota and blood metabolites in IBD
- Perplexing case of abdominal pain with eosinophilia and fasciitis
- Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B
- Butyrate-producing Faecalibacterium prausnitzii suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathway
- Novel mouse model for studying transmural intestinal fibrosis and creeping fat formation in stricturing Crohns disease
Esprimi il gradimento a questo contenuto
[Totale voti: 0 Media: 0]
